Presentation is loading. Please wait.

Presentation is loading. Please wait.

RESULTS TITLE; Prospective randomized controlled trial of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening protocol.

Similar presentations


Presentation on theme: "RESULTS TITLE; Prospective randomized controlled trial of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening protocol."— Presentation transcript:

1 RESULTS TITLE; Prospective randomized controlled trial of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening protocol for prostate cancer Authors; Rubio-Briones J 1, Casanova J 1, Dumont R 1, Fernandez-Serra A 2, Casanova-Salas I 2, Domínguez-Escrig J, Collado A 1, Ramírez-Backhaus 1, Gómez-Ferrer A 1, Iborra I 1, Monrós JL 1, Ricós JV 1, Solsona E 1, Lopez-Guerrero JA 2. 1 Departments of Urology and 2 Molecular Biology, Fundación Instituto Valenciano de Oncología, Valencia, Spain OBJECTIVESMETHODS CONCLUSIONS Results from the ERSPC with 11 years F-U have shown reduced number needed to screen and number needed to treat and improved cancer specific survival compared to the control arm but at the expense of too many negative biopsies 1 (Bx). In daily practice, we obtain maximum benefit from the use of PCA3 in the first biopsy 2. The role of PCA3 at a cut-off 35 has not been validated in an opportunistic screening scenario. OBJECTIVES; to test PCA3 as a second line biomarker with the main objective of saving biopsies, while reproducing the potential benefits of an opportunistic screening program. Local health authorities and our institutional ethics committee approved the trial, enclosed in our research and validation of novel biomarkers for prostate cancer (PCa) 3. Type of study; prospective and randomized Inclusion criteria; men aged between 40 and 75 years with > 10 years of life expectancy. Opportunistic screening with free adhesion, information and written consent for enrollment 1 st ; initial screening by PSA/digital rectal examination (DRE) performed by an urologist. 2 nd ; men with PSA <3ng/ml and a normal DRE were followed with PSA+DRE depending on PSA values (range 1-4 years) 3 rd ; PCA3 was performed in men with either an abnormal DRE or if PSA ≥3ng/ml. 4 th ; all men with PCA3 ≥35 were biopsied with an initial biopsy of 12 cores 5 th ; men with PCA3 < 35 were randomized 1:1 in a blinded manner whether either to biopsy (12 cores) or observation. Follow up of men with negative prostate biopsy ; first at 4-6 months depending on number of risk factors and then yearly. Re-biopsy criteria (16 cores); PSA increase >0.5ng/ml at 4-6 months or PSAv >0.75ng/ml/year. If PCA3 at a cut-off 35 was used as a second line biomarker within an opportunistic dual screening protocol, potentially 68.2% and 56.3% biopsies would have been saved at first round and at 23 months-FU, respectively We need longer FU to test the diagnostic and prognostic value of this dual protocol balancing saved biopsies and costs. Follow-up (FU); 23 months, having been included 2301men Mean age 57.5 (40-74) years-old Mean PSA; 1.51+/-1.50 ( )ng/ml Abnormal DE 10 men / PSA ≥3ng/ml 230 / Both 5 men Protocol morbidity; 10.65% Men submitted for PCA3; mean age 60.9+/- 6 y-o, mean PSA 4.8 +/- 2.3 ng/ml, mean PCA /- 9.1 Seventy-eight PCA3+ men (31.8%) were biopsied and PCa was identified in 29 (28 in first biopsy and one out of 8 FU-biopsies). In the randomized arm (167 PCA3- men), 96 were observed and 71 were biopsied. There were 8 PCa in 1 st biopsy and 3 more in 21 FU-biopsies. False negative rate of PCA3 at a cut-off 35 in this opportunistic dual protocol is 11.3% 1.-Schröder et al, N Eng J Med 2012; 366: , 2.- Rubio-Briones et al, Act Urol Esp 2011; 35(10): , 3.-This study is financed by grants FIS PI10/01206 and FI11/00505 from the Instituto de Salud Carlos III; ACOMP12/029, Generalitat Valenciana DRE (Urologist) + PSA months of recruitment (Oct 2010-Sep 2012) Normal DE and PSA < 3 ng/ml 2056 (89.35%) PCA3 Biopsy x 12 Men aged years-old with more than 10 years of life expectancy Abnormal DE and/or PSA ≥ (10.65%) Follow-up III DE and PSA in 4 months and then yearly Positive Bx:28 (35.9%) Randomization 1:1 PCA3 ≥ 35 n= 78 (31.8%) PCA3 < 35 n= 167 (68.2%) Negative Bx:50 (64.1%) Biopsy x 12 n = 71 No biopsy n = 96 Positive Bx: 8 (11.3%) Negative Bx: 63 (88.7%) Follow-up II DE and PSA in 6 months and then yearly Follow-up I; schedulled DE+ PSA: 1 year if initial PSA=2-3ng/ml 2 years if initial PSA = 1-2ng/ml 3 years if initial PSA = 0.5-1ng/ml 4 years if initial PSA = 0-0.5ng/ml Detection rates of PCa at first round in the PCA3+ and PCA3- groups were 35.9% and 11.3% respectively. Global detection rates for the PCA3+ and PCA3- men were 29/78 ptes (37.1%) and 11/167 ptes (6.5%) respectively with a mean FU of 8 months (range 2-22). Just 2 out of 8 PCA3 false negative patients at 1 st round had PCa Gleason ≥7, and during FU other 3 cases were detected, being 2 of them Gleason ≥7 PCa. These results make that potential missed Gleason ≥7 PCa rate in patients with PCA3- would be just 2.4% at 23 months of FU. If aproved, this protocol would save 167/245 biopsies (68.2%) at first round, 1st round Age (y-o) mean (range) PSA ng/ml Mean +/- stD (range) (range) Positivie cores Mean +/- stD RangeMedianGleason≥7 Tumoural % Mean +/- StD RangeMedian PCA3(+)35.9%28/7862.2(43-74) /- 2.7 (1, ,09) 2.9 +/- 2.2 (1-10)214/28(50%) /- 21% (8-83%)18.3% PCA3 (-)11.2%8/7160.2(46-74) 4,57 +/ (0,37-19,5) 3,3 +/- 3.1 (1-10)2 2/8 (25%) (both 3+4) /- 25.6% (10-83%)18.3% Follow-up13,7% 4/29 63,5 (60-66) 5,4 (4,5-5-8) 2 (1-3) 2/41,2% (0,64-1,61) PCA3 (+) 1/812,5%665,5101,61 PCA3 (-) 3/2114,2%62,5(60-66)5,3(4,54-5,75)1,6(1-3)21,1(0,64-1,54) GLEASON SCORE 1st round Nº Bx (+) PCA3 mean (range) =< PCA3(+)28/78 79,8 (35-206) PCA3(-)8/7121,4(13-32)62- Follow-up PCA3(+)1/ PCA3(-)3/21 19,3 (11,15,32) 111 CLINICO-PATHOLOGICAL DATA FROM BIOPSIES P-10


Download ppt "RESULTS TITLE; Prospective randomized controlled trial of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening protocol."

Similar presentations


Ads by Google